Bicycle Therapeutics Plc ADR (NASDAQ: BCYC) kicked off on Friday, up 3.78% from the previous trading day, before settling in for the closing price of $24.37. Over the past 52 weeks, BCYC has traded in a range of $12.54-$27.24.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 38.55% over the past five years. While this was happening, its average annual earnings per share was recorded 17.50%. With a float of $42.13 million, this company’s outstanding shares have now reached $42.43 million.
Let’s look at the performance matrix of the company that is accounted for 284 employees.
Bicycle Therapeutics Plc ADR (BCYC) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Bicycle Therapeutics Plc ADR is 1.19%, while institutional ownership is 93.15%. The most recent insider transaction that took place on Jul 03 ’24, was worth 62,730. In this transaction CHIEF EXECUTIVE OFFICER of this company sold 3,194 shares at a rate of $19.64, taking the stock ownership to the 384,076 shares. Before that another transaction happened on Jul 03 ’24, when Company’s CHIEF TECHNOLOGY OFFICER sold 967 for $19.64, making the entire transaction worth $18,992. This insider now owns 93,917 shares in total.
Bicycle Therapeutics Plc ADR (BCYC) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 3/31/2024, the organization reported -1.41 earnings per share (EPS), lower than consensus estimate (set at -1.29) by -0.12. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.17 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 17.50% per share during the next fiscal year.
Bicycle Therapeutics Plc ADR (NASDAQ: BCYC) Trading Performance Indicators
Take a look at Bicycle Therapeutics Plc ADR’s (BCYC) current performance indicators. Last quarter, stock had a quick ratio of 10.42. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 25.89.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.46, a number that is poised to hit -1.11 in the next quarter and is forecasted to reach -4.82 in one year’s time.
Technical Analysis of Bicycle Therapeutics Plc ADR (BCYC)
Bicycle Therapeutics Plc ADR (NASDAQ: BCYC) saw its 5-day average volume 0.34 million, a positive change from its year-to-date volume of 0.33 million. As of the previous 9 days, the stock’s Stochastic %D was 81.72%. Additionally, its Average True Range was 1.42.
During the past 100 days, Bicycle Therapeutics Plc ADR’s (BCYC) raw stochastic average was set at 80.37%, which indicates a significant decrease from 89.58% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 42.71% in the past 14 days, which was lower than the 48.74% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $22.37, while its 200-day Moving Average is $20.38. Nevertheless, the first resistance level for the watch stands at $26.77 in the near term. At $28.24, the stock is likely to face the second major resistance level. The third major resistance level sits at $30.78. If the price goes on to break the first support level at $22.76, it is likely to go to the next support level at $20.22. Assuming the price breaks the second support level, the third support level stands at $18.75.
Bicycle Therapeutics Plc ADR (NASDAQ: BCYC) Key Stats
The company with the Market Capitalisation of 1.08 billion has total of 42,779K Shares Outstanding. Its annual sales at the moment are 26,980 K in contrast with the sum of -180,660 K annual income. Company’s last quarter sales were recorded 19,530 K and last quarter income was -26,560 K.
